ENTPD1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P12402(ENTPD1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12402(ENTPD1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1), also known as CD39. is a cell surface enzyme encoded by the *ENTPD1* gene. As a member of the ectonucleoside triphosphate diphosphohydrolase family, it plays a critical role in purinergic signaling by hydrolyzing extracellular ATP and ADP into AMP, which is subsequently converted to adenosine by CD73 (ecto-5'-nucleotidase). This enzymatic activity regulates immune responses by modulating extracellular nucleotide levels, thereby influencing purinergic receptor signaling pathways. CD39 is highly expressed on immune cells, including regulatory T cells (Tregs), dendritic cells, and tumor-infiltrating lymphocytes, as well as endothelial cells.

ENTPD1 antibodies are essential tools for studying the protein's expression, function, and therapeutic potential. They are widely used in research to investigate CD39's role in immune tolerance, inflammation, and cancer. In the tumor microenvironment, CD39 contributes to immunosuppression by generating adenosine, which dampens effector T cell activity and promotes tumor immune evasion. Consequently, CD39 is considered a promising target for cancer immunotherapy, with blocking antibodies being explored to enhance antitumor immunity. Additionally, CD39 antibodies aid in understanding its involvement in autoimmune diseases, cardiovascular disorders, and thrombotic conditions linked to dysregulated purinergic signaling. These antibodies are validated for applications such as flow cytometry, immunohistochemistry, and functional assays, supporting both basic research and drug development efforts.